WO2003007909A2 - Preparations cosmetiques ou medicales a effet rafraichissant durable - Google Patents

Preparations cosmetiques ou medicales a effet rafraichissant durable Download PDF

Info

Publication number
WO2003007909A2
WO2003007909A2 PCT/EP2002/007788 EP0207788W WO03007909A2 WO 2003007909 A2 WO2003007909 A2 WO 2003007909A2 EP 0207788 W EP0207788 W EP 0207788W WO 03007909 A2 WO03007909 A2 WO 03007909A2
Authority
WO
WIPO (PCT)
Prior art keywords
polyethylene glycol
acid
ether
cosmetic
preparations
Prior art date
Application number
PCT/EP2002/007788
Other languages
German (de)
English (en)
Other versions
WO2003007909A3 (fr
Inventor
Andreas Schäfer
Andreas Bleckmann
Boris Syskowski
Original Assignee
Beiersdorf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf Ag filed Critical Beiersdorf Ag
Publication of WO2003007909A2 publication Critical patent/WO2003007909A2/fr
Publication of WO2003007909A3 publication Critical patent/WO2003007909A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/24—Thermal properties
    • A61K2800/244—Endothermic; Cooling; Cooling sensation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Definitions

  • the present invention relates to cosmetic and dermatological preparations with a long-lasting cooling effect, in particular skin-care cosmetic and dermatological preparations.
  • the skin is the largest human organ. Among its many functions (for example for heat regulation and as a sensory organ), the barrier function that prevents the skin (and ultimately the entire organism) from drying out is probably the most important. At the same time, the skin acts as a protective device against the penetration and absorption of substances coming from outside. This barrier function is brought about by the epidermis, which as the outermost layer forms the actual protective cover against the environment. At around a tenth of the total thickness, it is also the thinnest layer of the skin.
  • the outermost layer of the epidermis is of particular importance as an important barrier layer. for protection against environmental influences and dehydration.
  • the horny layer is constantly worn out in contact with the environment and must therefore be renewed continuously.
  • the corneocytes horn cells
  • the complex lipid membrane in the intercellular spaces corresponds to the mortar.
  • the epidermal lipids In addition to their barrier effect against external chemical and physical influences, the epidermal lipids also contribute to the cohesion of the horny layer and have an influence on the smoothness of the skin. In contrast to the sebum lipids, which do not form a closed film on the skin, the epidermal lipids are distributed over the entire horny layer.
  • Cosmetic skin care is primarily understood to mean that the natural function of the skin as a barrier against environmental influences (e.g. dirt, chemicals, microorganisms) and against the loss of the body's own substances (e.g. water, natural fats, electrolytes) is strengthened or restored.
  • environmental influences e.g. dirt, chemicals, microorganisms
  • loss of the body's own substances e.g. water, natural fats, electrolytes
  • the aim of skin care is also to compensate for the loss of fat and water in the skin caused by daily washing. This is especially important when the natural regeneration ability is insufficient.
  • skin care products are intended to protect against environmental influences, particularly sun and wind, and to delay skin aging.
  • Medical topical compositions usually contain one or more drugs in effective concentration.
  • Common cosmetic dosage forms are emulsions, that is, metastable two- or multi-phase systems in which the individual phases are in the liquid state.
  • the most common emulsions are O / W and W / O emulsions.
  • More rare forms of administration are multiple emulsions, i.e. those which themselves contain droplets of a further dispersed phase in the droplets of the dispersed (or discontinuous) phase, e.g. W / O / W emulsions and O / W / O emulsions.
  • emulsifiers In order to guarantee the metastability of emulsions, surface-active substances, i.e. emulsifiers, are generally necessary.
  • emulsifier-free preparations which, for example, have oil droplets dispersed in an aqueous phase, similar to an O / W emulsion.
  • a prerequisite for this may be that the continuous aqueous phase has a gel structure stabilizing the dispersed phase and other circumstances more.
  • Such systems are sometimes called hydrodispersions or oleodispersions, depending on which is the disperse phase and which is the continuous phase.
  • Gels are the usual and increasingly popular cosmetic and dermatological preparation forms.
  • gels are understood to mean: Relatively dimensionally stable, easily deformable disperse systems composed of at least two components, which as a rule consist of a - usually solid - colloidally divided substance made up of long-chain molecular groups (e.g. gelatin, silica, polysaccharides) as a scaffold and a liquid dispersant (e.g. water) exist.
  • the colloidally divided substance is often referred to as a thickening or gelling agent. It forms a spatial network in the dispersant, whereby individual colloidal particles are involved via electrostatic interaction. can be more or less firmly linked.
  • the dispersing agent that surrounds the network is characterized by electrostatic affinity for the gelling agent, ie a predominantly polar (in particular: hydrophilic) gelling agent preferably gels a polar dispersing agent (in particular: water), whereas a predominantly non-polar gelling agent preferably gels non-polar dispersing agent.
  • a predominantly polar (in particular: hydrophilic) gelling agent preferably gels a polar dispersing agent (in particular: water)
  • a predominantly non-polar gelling agent preferably gels non-polar dispersing agent.
  • Lipogels and oleogels are also common in cosmetic and pharmaceutical galenics.
  • oleogels which are practically anhydrous
  • hydrogels which are practically fat-free.
  • gels are transparent.
  • gels are usually characterized by a semi-solid, often flowable consistency.
  • surfactant gels are also common preparations of the prior art. This is understood to mean systems which, in addition to water, have a high concentration of emulsifiers, typically more than about 25% by weight, based on the overall composition. If oil components are solubilized in these surfactant gels, also called “surfactant gels” in technical terms, microemulsion gels are obtained, which are also referred to as “ringing gels”. By adding nonionic emulsifiers, for example alkyl polyglycosides, it is possible to obtain cosmetically more elegant microemulsion gels.
  • the cooling effect of cosmetic preparations has so far been based on two basic principles: Use of components which volatilize in gaseous form after topical application and remove the required amount of energy, the so-called enthalpy of vaporization, for the most part from the skin surface. Suitable liquid components are therefore used in corresponding non-occlusive cosmetics. Ethanol has proven to be particularly suitable here, and formulations with a high water content also have a clear cooling effect.
  • cooling agents that interact with the skin's heat receptors and thus trigger a feeling of cold without generating a measurable physical cooling.
  • menthol and various menthol derivatives are used for this.
  • high ethanol contents as well as menthol and its derivatives are not suitable for numerous applications from an olfactory point of view, in addition to their irritative potential, in particular because of their distinct odor. Frequently enough, such substances also cause an increase in blood circulation, which on the contrary creates a feeling of warmth.
  • cooling agents In the literature, for example, ionic compounds, especially ammonium salts, are described as cooling agents. Isopropanolic gels with camphor and menthol additives are also widely used as cooling preparations.
  • the object of the present invention was therefore to provide nourishing cosmetic and medical preparations which do not have the disadvantages of the prior art, in particular those which, when applied to the skin or mucous membranes, have a moisturizing and / or cooling effect.
  • cooling cosmetic or medical topical preparations characterized by a content of methyl palmitate, eliminate the disadvantages of the prior art.
  • methyl palmitate for the production of cooling cosmetic or medical topical preparations is also.
  • These preparations according to the invention develop their cooling effect within a wide range of use concentrations of the methyl palmitate, for example 0.5-50% by weight, advantageously 1-20% by weight, based on the total weight of the preparations. They are easy to formulate and make no great demands on manufacturing processes.
  • cooling active ingredients for example menthol or menthol derivatives for sensory modification or for enhancing the cooling effect, can optionally be added to the preparations according to the invention.
  • preparations containing the active compound combinations according to the invention, customary antioxidants can be used.
  • the antioxidants are advantageously selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg uro- canic acid) and their derivatives, peptides such as D, L-carnosine, D-camosine, L-carnosine and their derivatives (e.g. anserine), carotenoids, carotenes (e.g. ⁇ -carotene, ⁇ -carotene, lycopene) and their derivatives, lipoic acid and their derivatives (e.g. dihydroliponic acid), aurothioglucose, propylthiouracil and other thiols (e.g.
  • thioredoxin glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl, and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters) as well as their salts, dilauryl thiodipropionate, distearyl thio dipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfates oximine compounds (eg buthioninsulfoximines, homocysteine sulfoximine, buthioninsulfones, penta-, hexa-, heptathioninsulfoximine) in very low tolerable doses (eg pmol toler
  • citric acid lactic acid, malic acid
  • humic acid bile acid
  • bile extracts bilirubin
  • biliverdin biliverdin
  • EDTA EGTA and their derivatives
  • unsaturated fatty acids and their derivatives e.g.
  • ⁇ -linolenic acid, linoleic acid, oleic acid), folic acid and its derivatives Alanine diacetic acid, flavonoids, polyphenols, catechins, vitamin C and derivatives (eg ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (eg vitamin E acetate), as well as coniferyl benzoate of the benzoin resin, rutinic acid and its derivatives, ferrous acid and their derivatives, butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguajak resin acid, nordihydroguajaretic acid, trihydroxybutyrophenone, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (eg ZnO, ZnS0) selenium and its derivatives (eg selenium methionine, their derivatives) eg stilbene oxide, trans-style benoxid
  • the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 to 20% by weight, in particular 1 to 10% by weight, based on the total weight of the preparation ,
  • the prophylaxis or the cosmetic or dermatological treatment with the active ingredient used according to the invention or with the cosmetic or topical dermatological preparations with an effective content of active ingredient used according to the invention is carried out in the usual way, in such a way that the invented active ingredient used according to the invention or the cosmetic or topical dermatological preparations with an effective content of active ingredient used according to the invention is applied to the affected skin areas.
  • the active ingredient used according to the invention can advantageously be incorporated into customary cosmetic and dermatological preparations, which can be in various forms. So you can e.g. a solution, an emulsion of the type water-in-oil (W / O) or of the type oil-in-water (O / W), or a multiple emulsions, for example of the type water-in-oil-in-water (W / O / W) or oil-in-water-in-oil (OW / O), a hydro-dispersion or lipodispersion, a gel, a solid stick or an aerosol.
  • W / O type water-in-oil
  • O oil-in-water
  • OW / O oil-in-water-in-oil
  • Emulsions according to the invention in the sense of the present invention are advantageous and contain e.g. Fats, oils, waxes and / or other fat bodies, as well as water and one or more emulsifiers, as are usually used for such a type of formulation.
  • Medical topical compositions in the sense of the present invention generally contain one or more medicaments in an effective concentration.
  • the one For the sake of convenience, reference is made to the legal provisions of the Federal Republic of Germany for a clear distinction between cosmetic and medical use and corresponding products (e.g. cosmetics regulation, food and drug law).
  • cosmetic or topical dermatological compositions within the meaning of the present invention, depending on their structure, can be used, for example, as skin protection cream, cleansing milk, sunscreen lotion, nutritional cream, day or night cream, etc. It may be possible and advantageous to add the compositions according to the invention as the basis for pharmaceutical formulations use.
  • cosmetic and dermatological preparations which are in the form of a sunscreen are also favorable.
  • these preferably additionally contain at least one UVA filter substance and / or at least one UVB filter substance and / or at least one inorganic pigment.
  • UV-A or UV-B filter substances are usually incorporated into day creams.
  • Preparations according to the invention can advantageously contain substances which absorb UV radiation in the UVB range, the total amount of filter substances e.g. 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, in particular 1 to 6% by weight, based on the total weight of the preparations.
  • the UVB filters can be oil-soluble or water-soluble.
  • oil-soluble substances for example:
  • 4-aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
  • Esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
  • Esters of salicylic acid preferably salicylic acid (2-ethylhexyl) ester, salicylic acid
  • Esters of benzalmalonic acid preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester;
  • Sulfonic acid derivatives of benzophenones preferably 2-hydroxy-4-methoxy-benzophenone-5-sulfonic acid and their salts;
  • Sulfonic acid derivatives of 3-benzylidene camphor e.g. 4- (2-oxo-3-bornylidene-methyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bomylidene-methyl) sulfonic acid and their salts.
  • UVB filters which can be used according to the invention, is of course not intended to be limiting.
  • the invention also relates to the combination of a UVA filter according to the invention with a UVB filter or a cosmetic or dermatological preparation according to the invention which also contains a UVB filter.
  • UVA filters in the preparations according to the invention, which are usually contained in cosmetic and / or dermatological preparations.
  • Such filter substances are preferably derivatives dibenzoylmethane, in particular 1- (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1,3-dione and 1-phenyl-3- (4'-isopropylphenyl) propane-1, 3-dione. Preparations containing these combinations are also the subject of the invention.
  • the same amounts of UVA filter substances that were mentioned for UVB filter substances can be used.
  • Cosmetic and / or dermatological preparations in the sense of the present invention can also contain inorganic pigments which are usually used in cosmetics to protect the skin from UV rays. These are oxides of titanium, zinc, iron, zirconium, silicon, manganese, aluminum, cerium and mixtures thereof, as well as modifications in which the oxides are the active agents. It is particularly preferred to use pigments based on titanium dioxide. The amounts given for the above combinations can be used.
  • the cosmetic preparations according to the invention can contain cosmetic auxiliaries as are usually used in such preparations, e.g. Preservatives, bactericides, deodorizing substances, antiperspirants, insect repellents, vitamins, anti-foaming agents, dyes, pigments with a coloring effect, thickeners, softening substances, moisturizing and / or moisturizing substances, fats, oils, waxes or other common components of a cosmetic Formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • cosmetic auxiliaries e.g. Preservatives, bactericides, deodorizing substances, antiperspirants, insect repellents, vitamins, anti-foaming agents, dyes, pigments with a coloring effect, thickeners, softening substances, moisturizing and / or moisturizing substances, fats, oils, waxes or other common components of a cosmetic Formulation such as alcohols, polyols, polymers, foam stabilize
  • Preparations according to the invention can also advantageously contain substances which absorb UV radiation in the UVB range, the total amount of the filter substances being, for example, 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, in particular 1.0 to 6.0% by weight, based on the total weight of the preparations, in order to provide cosmetic preparations which protect the hair or the skin from the entire range of ultraviolet radiation. They can also serve as a sunscreen for the hair. If the preparations according to the invention contain UVB filter substances, they can be oil-soluble or water-soluble. Oil-soluble UVB filters which are advantageous according to the invention are, for example:
  • 4-aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
  • Esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
  • esters of salicylic acid preferably salicylic acid (2-ethylhexyl) ester, salicylic acid (4-isopropylbenzyl) ester, salicylic acid homomethyl ester,
  • Esters of benzalmalonic acid preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester,
  • Salts of 2-phenylbenzimidazole-5-sulfonic acid such as its sodium, potassium or triethanolammonium salt, and also the sulfonic acid itself;
  • Sulfonic acid derivatives of benzophenones preferably 2-hydroxy-4-methoxy-benzophenone-5-sulfonic acid and their salts;
  • Sulfonic acid derivatives of 3-benzylidene camphor e.g. 4- (2-oxo-3-bornylidene-methyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bornylidene-methyl) sulfonic acid and their salts and 1,4-di (2-oxo-10-sulfo 3-bomylidene-methyl) -benzene and its salts (the corresponding 10-sulfato compounds, e.g. the corresponding sodium, potassium or triethanolammonium salt), also as benzene-1,4-di (2-oxo-3-bomylidene-methyl- Designated 10-sulfonic acid
  • UVB filters which can be used in combination with the active compound combinations according to the invention, is of course not intended to be limiting. It can also be advantageous to use UVA filters that are usually contained in cosmetic preparations. These substances are preferably derivatives of dibenzoylmethane, in particular 1- (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1,3-dione and 1-phenyl-3- (4'-isopropylphenyl) propane-1,3-dione. The quantities used for the UVB combination can be used.
  • Cosmetic and dermatological preparations according to the invention advantageously also contain inorganic pigments based on metal oxides and / or other metal compounds which are sparingly soluble or insoluble in water, in particular the oxides of titanium (TiO 2 ), zinc (ZnO), iron (eg Fe 2 O 3 ), zirconium (ZrO 2 ), silicon (SiO 2 ), manganese (for example MnO), aluminum (Al 2 O 3 ), cerium (for example Ce 2 O 3 ), mixed oxides of the corresponding metals and mixtures of such oxides. Pigments based on TiO 2 are particularly preferred.
  • the inorganic pigments are in hydrophobic form, i.e. that they have been treated to be water-repellent on the surface.
  • This surface treatment can consist in that the pigments are provided with a thin hydrophobic layer by methods known per se.
  • One such method consists, for example, in that the hydrophobic surface layer after a rectification
  • n and m are stoichiometric parameters to be used at will, R and R 'are the desired organic radicals.
  • hydrophobized pigments shown in analogy to DE-OS 33 14 742 are advantageous.
  • Advantageous TiO 2 pigments are available, for example, under the trade names MT 100 T from TAYCA, M 160 from Kemira and T 805 from Degussa.
  • Preparations according to the invention can also contain anionic, nonionic and / or amphoteric surfactants, especially if crystalline or microcrystalline solids, for example inorganic micropigments, are to be incorporated into the preparations according to the invention.
  • Surfactants are amphiphilic substances that can dissolve organic, non-polar substances in water.
  • hydrophilic parts of a surfactant molecule are mostly polar functional groups, for example -COO " , -OS ⁇ 3 2" , -SO 3 " , while the hydrophobic parts generally represent non-polar hydrocarbon residues.
  • Surfactants are generally classified according to Art and charge of the hydrophilic part of the molecule. There are four groups:
  • Anionic surfactants generally have carboxylate, sulfate or sulfonate groups as functional groups. In an aqueous solution they form negatively charged organic ions in an acidic or neutral environment. Cationic surfactants are characterized almost exclusively by the presence of a quaternary ammonium group. In aqueous solution they form positively charged organic ions in an acidic or neutral environment. Amphoteric surfactants contain both anionic and cationic groups and accordingly behave like anionic or cationic surfactants in aqueous solution depending on the pH. They have a positive charge in a strongly acidic environment and a negative charge in an alkaline environment. In the neutral pH range, however, they are zwitterionic, as the following example should illustrate:
  • B + any cation, e.g. Na +
  • Polyether chains are typical of non-ionic surfactants.
  • Non-ionic surfactants do not form ions in an aqueous medium.
  • acylglutamates for example sodium acylglutamate, di-TEA-palmitoylaspartate and sodium caprylic / capric glutamate,
  • acyl peptides for example palmitoyl-hydrolyzed milk protein, sodium cocoyl-hydrolyzed soy protein and sodium / potassium cocoyl-hydrolyzed collagen,
  • sarcosinates for example myristoyl sarcosin, TEA-lauroyl sarcosinate, sodium lauroyl sarcosinate and sodium cocoyl sarcosinate,
  • taurates for example sodium lauroyl taurate and sodium methyl cocoyl taurate
  • carboxylic acids for example lauric acid, aluminum stearate, magnesium alkanolate and zinc undecylenate,
  • ester carboxylic acids for example calcium stearoyl lactylate, laureth-6 citrate and sodium PEG-4 lauramide carboxylate,
  • ether carboxylic acids for example sodium laureth-13 carboxylate and sodium PEG-6 cocamide carboxylate,
  • Phosphoric acid esters and salts such as DEA-oleth-10-phosphate and dilureth-4-phosphate
  • acyl isethionates e.g. Sodium / ammonium cocoyl isethionate
  • alkylsulfonates for example, sodium sulfonate C-fin sodium cocomonoglyceride 12-i4 olefinsulfonates, sodium lauryl sulfoacetate and magnesium PEG-3 cocamide sulfate,
  • Sulfosuccinates for example dioctyl sodium sulfosuccinate, disodium laureth sulfosuccinate, disodium lauryl sulfosuccinate and disodium undecylenamido MEA sulfosuccinate as well as sulfuric acid esters, such as
  • alkyl ether sulfate for example sodium, ammonium, magnesium, MIPA, TIPA laureth sulfate, sodium and sodium C12 pareth ⁇ 3,
  • Alkyl sulfates for example sodium, ammonium and TEA lauryl sulfate.
  • Quaternary surfactants contain at least one N atom which is covalently linked to 4 alkyl or aryl groups. Regardless of the pH value, this leads to a positive charge.
  • Alkyl betaine, alkyl amidopropyl betaine and alkyl amidopropyl hydroxysulfain are advantageous.
  • the cationic surfactants used in the invention can also preferably be chosen from the group of quaternary ammonium compounds, especially benzyltrialkylammonium chlorides or bromides, such as rylammoniumchlorid Benzyldimethylstea-, further alkyltrialkylammonium salts, for example cetyltrimethylammonium chloride or bromide, niumchloride Alkyldimethylhydroxyethylammo- or bromides, dialkyldimethylammonium chlorides or bromides , Alkylamid-ethyltrimethylammonium ether sulfates, alkylpyridinium salts, for example lauryl or cetyipyrimidinium chloride, imidazoline derivatives and compounds with a cationic character such as amine oxides, for example alkyldimethylamine oxides or alkylaminoethyldimethylamine oxides. Cetyltrimethylammonium salts are particularly
  • acyl / dialkyl ethylenediamine for example sodium acyl amphoacetate, disodium acyl amphodipropionate, disodium alkyl amphodiacetate, sodium acylamphohydroxy propyl sulfonate, disodium acyl amphodiacetate and sodium acyl amphopropionate
  • N-alkylamino acids for example aminopropylalkylglutamide, alkylaminopropionic acid, sodium alkylimidodipropionate and lauroamphocarboxyglycinate.
  • alkanolamides such as cocamides MEA / DEA / MIPA
  • amine oxides such as cocoamidopropylamine oxide
  • esters which are formed by esterification of carboxylic acids with ethylene oxide, glycerol, sorbitan or other alcohols,
  • ethers for example ethoxylated / propoxylated alcohols, ethoxylated / propoxylated esters, ethoxylated / propoxylated glycerol esters, ethoxylated / propoxylated cholesterol esters, ethoxylated / propoxylated triglyceride esters, ethoxylated propoxylated lanolin, ethoxylated / propoxylated polysiloxanes, propoxylated POE ethers and alu alkyl polyglycosides such as lauryl glucoside, decyl glycoside and cocoglycoside.
  • the surface-active substance can be present in the preparations according to the invention in a concentration between 1 and 95% by weight, based on the total weight of the preparations.
  • Oils such as triglycerides of capric or caprylic acid as well as natural oils such as e.g. Castor oil;
  • Fats, waxes and other natural and synthetic fat bodies preferably
  • Esters of fatty acids with alcohols with a low C number e.g. with isopropanol, propyl lenglycol or glycerin, or esters of fatty alcohols with lower C- alkanoic acids
  • Silicone oils such as dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes and mixed forms thereof.
  • the oil phase of the emulsions of the present invention is advantageously selected from the group of the esters from saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols a chain length of 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols of a chain length of 3 to 30 carbon atoms.
  • ester oils can then advantageously be selected from the group of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononylisononanoate, 2-ethyl-2-ethylhexyl palmitate 2-octyldodecyl palmitate, oleyl oleate, olerlerucate, erucyl oleate, erucylerucate and synthetic, semisynthetic and natural mixtures of such esters, for example Jojoba oil.
  • the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and also the fatty acid triglycerides, especially the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 - 18 carbon atoms.
  • the fatty acid triglycerides can, for example, advantageously be selected from the group of synthetic, semisynthetic and natural oils, e.g. Olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like.
  • oil phase is advantageously chosen from the group consisting of 2-ethylhexyl isostearate, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C 2-15 alkyl benzoate, caprylic capric acid triglyceride, dicaprylyl ether.
  • Mixtures of C 12-15 alkyl benzoate and 2-ethylhexyl isostate are particularly advantageous, mixtures of C 12 . 15 alkyl benzoate and isotridecyl isononanoate and mixtures of C 12-15 alkyl benzoate, 2-ethylhexyl isostearate and isotridecyl isononanoate.
  • hydrocarbons paraffin oil, squalane and squalene can be used advantageously for the purposes of the present invention.
  • the oil phase can advantageously also have a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils.
  • Such silicones or silicone oils can be present as monomers, which are generally characterized by structural elements, as follows:
  • the silicon atoms can be substituted with the same or different alkyl residues and / or aryl residues, which are represented here generally by the residues R, - R (to say that the number of different residues is not necessarily limited to up to 4), m can assume values from 2 - 200,000.
  • Cyclic silicones to be used advantageously according to the invention are generally characterized by structural elements as follows wherein the silicon atoms can be substituted with the same or different alkyl radicals and / or aryl radicals, which are generally represented here by the radicals R ⁇ - R 4 (to say that the number of different radicals is not necessarily limited to up to 4) , n can assume values from 3/2 to 20. Broken values for n take into account that there may be odd numbers of siloxyl groups in the cycle.
  • Cyclomethicone e.g. decamethylcyclopentasiloxane
  • silicone oils can also be used advantageously for the purposes of the present invention, for example undecamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane), cetyldimethicone, behenoxydimethicone.
  • silicone oils of a similar constitution to the compounds described above, the organic side chains of which are derivatized, for example polyethoxylated and / or polypropoxylated.
  • these include, for example, polysiloxane-polyalkyl-polyether copolymers such as the cetyl-dimethicone copolyol, the (cetyl-dimethicone copolyol (and) polyglyceryl-4-isostearate (and) hexyl laurate)
  • the aqueous phase of the preparations according to the invention optionally advantageously contains alcohols, diols or polyols of low C number, and their ethers, preferably Ethanol, isopropanol, propylene glycol, glycerin, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analogous products, furthermore alcohols with a low C number, e.g. ethanol, isopropanol, 1, 2-propanediol, glycerol and in particular one or more thickeners, which one or more can advantageously be selected from the group consisting of silicon dioxide and aluminum silicates.
  • alcohols, diols or polyols of low C number, and their ethers preferably Ethanol, isopropanol, propylene glycol, glycerin,
  • Preparations according to the invention which are present as emulsions particularly advantageously contain one or more hydrocolloids.
  • hydrocolloids can advantageously be selected from the group of the gums, polysaccharides, cellulose derivatives, layered silicates, polyacrylates and / or other polymers.
  • Preparations according to the invention which are present as hydrogels contain one or more hydrocolloids. These hydrocolloids can advantageously be selected from the aforementioned group.
  • Gums include plant or tree sap that harden in the air and form resins or extracts from aquatic plants. Gum arabic, locust bean gum, tragacanth, karaya, guar gum, pectin, gellan gum, carrageenan, agar, algine, chondrus, xanthan gum can advantageously be selected from this group for the purposes of the present invention.
  • derivatized gums such as e.g. Hydroxypropyl guar (Jaguar® HP 8).
  • polysaccharides and derivatives are e.g. Hyaluronic acid, chitin and chitosan, chondroitin sulfates, starch and starch derivatives.
  • cellulose derivatives are e.g. Methyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose.
  • Layered silicates include naturally occurring and synthetic clays such as montmorillonite, bentonite, hectorite, laponite and magnesium aluminum silicates such as Veegum®. These can be used as such or in modified form such as stearylalkonium hectorites.
  • silica gels can also advantageously be used.
  • the polyacrylates include e.g. Carbopol types from Goodrich (Carbopol 980, 981, 1382, 5984, 2984, EDT 2001 or Pemulen TR2).
  • polymers e.g. Polyacrylamides (Seppigel 305), polyvinyl alcohols, PVP, PVP / VA copolymers, polyglycols.
  • Preparations according to the invention in the form of emulsions contain one or more emulsifiers.
  • emulsifiers can advantageously be selected from the group of nonionic, anionic, cationic or amphoteric emulsifiers.
  • the nonionic emulsifiers include a) partial fatty acid esters and fatty acid esters of polyhydric alcohols and their ethoxylated derivatives (e.g. glyceryl monostearates, sorbitan stearates, glyceryl stearyl citrates, sucrose stearyl citrates, b) ethoxylated fatty alcohols and fatty acids c) alkyl acid phenol amide fatty amides, fatty acid glycol amides, fatty acid glycol amides, fatty acid glycol amides, fatty acid glycol amides, fatty acid glycol amides, fatty acid glycol amides, fatty acid glycol amides, e.g. Triton X)
  • the anionic emulsifiers include a) soaps (e.g. sodium stearate) b) fatty alcohol sulfates c) mono-, di- and trialkylphosphonic acid esters and their ethoxylates
  • the cationic emulsifiers include a) quaternary ammonium compounds with a long-chain aliphatic radical, e.g. Distearyldimonium Chloride
  • amphoteric emulsifiers include a) alkylamininoalkane carboxylic acids b) betaines, sulfobetaines c) imidazoline derivatives
  • emulsifiers which include beeswax, wool wax, lecithin and steroids.
  • O / W emulsifiers can, for example, advantageously be selected from the group of polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated products, for example: the fatty alcohol ethoxylates of the ethoxylated wool wax alcohols, the polyethylene glycol ethers of the general formula R-0 - (- CH 2 -CH 2 - 0-) n -R ', the fatty acid ethoxylates of the general formula
  • R-0 - (- CH 2 -CH 2 -0-) ⁇ -CH 2 -C00H and n represent a number from 5 to 30, the polyoxyethylene sorbitol fatty acid esters, the alkyl ether sulfates of the general formula R-0 - (- CH 2 -CH 2 -0-) n -S0 3 -H of the fatty alcohol propoxylates of the general formula
  • the polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated O / W emulsifiers selected are particularly advantageously selected from the group of substances with HLB values of 11-18, very particularly advantageously with HLB values of 14.5-15. 5, provided the O / W emulsifiers have saturated radicals R and R '. If the O / W emulsifiers have unsaturated radicals R and / or R ', or if isoalkyl derivatives are present, the preferred HLB value of such emulsifiers can also be lower or higher.
  • fatty alcohol ethoxylates from the group of the ethoxylated stearyl alcohols, cetyl alcohols, cetylstearyl alcohols (cetearyl alcohols).
  • cetyl alcohols cetylstearyl alcohols
  • cetearyl alcohols cetearyl alcohols
  • Polyethylene glycol (12) lauryl ether (Laureth-12), polyethylene glycol (12) isolauryl ether (Isolureth-12).
  • Sodium laureth-11 carboxylate can advantageously be used as the ethoxylated alkyl ether carboxylic acid or its salt.
  • Sodium laureth 1-4 sulfate can advantageously be used as alkyl ether sulfate.
  • Polyethylene glycol (30) cholesteryl ether can advantageously be used as the ethoxylated cholesterol derivative.
  • Polyethylene glycol (25) soyasterol has also proven itself.
  • polyethylene glycol glycerol fatty acid esters from the group polyethylene glycol (20) glyceryl laurate, polyethylene glycol (21) glyceryl laurate, polyethylene glycol (22) glyceryl laurate, polyethylene glycol (23) glyceryl laurate, polyethylene glycol (6) glyceryl capethylene / caprinate 20 ) glyceryl oleate, polyethylene glycol (20) glyceryl isostearate, polyethylene glycol (18) glyceryl oleate / cocoate.
  • sorbitan esters from the group polyethylene glycol (20) sorbitan monolaurate, polyethylene glycol (20) sorbitan monostearate, polyethylene glycol (20) sorbitan monoisostearate, polyethylene glycol (20) sorbitan monopalmitate, polyethylene glycol (20) sorbitan monooleate.
  • W / O emulsifiers that can be used are: fatty alcohols with 8 to 30 carbon atoms, monoglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12-18, carbon atoms, diglycerol esters saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 - 18 C atoms, monoglycerol ethers saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12 - 18 C - Atoms, diglycerol ethers of saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12-18 C atoms, propylene glycol esters of saturated and / or unsaturated, branched and /
  • W / O emulsifiers are glyceryl stearate Glycerylmonoiso-, glyceryl monomyristate, glyceryl, diglyceryl monostearate, Diglyceryl- monoisostearate, colmonocaprylat propylene glycol, propylene glycol monoisostearate glycol, propylene, propylene glycol, sorbitan, Sorbitanmo- monolaurate, sorbitan, Sorbitanmonoisooleat, sucrose, cetyl alcohol, Stearyl alcohol, arachidyl alcohol, behenyl alcohol, isobehenyl alcohol, selachyl alcohol, chimyl alcohol, polyethylene glycol (2) stearyl ether (steareth-2), glyceryl monoiaurate, glyceryl monocaprinate, glyceryl monocaprylate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des préparations topiques cosmétiques ou médicales à effet rafraîchissant, caractérisées en ce qu'elles contiennent du palmitate de méthyle.
PCT/EP2002/007788 2001-07-17 2002-07-12 Preparations cosmetiques ou medicales a effet rafraichissant durable WO2003007909A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10134603.4 2001-07-17
DE2001134603 DE10134603A1 (de) 2001-07-17 2001-07-17 Kosmetische oder dermatologische Zubereitungen mit langanhaltender kühlender Wirkung

Publications (2)

Publication Number Publication Date
WO2003007909A2 true WO2003007909A2 (fr) 2003-01-30
WO2003007909A3 WO2003007909A3 (fr) 2003-12-04

Family

ID=7691998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/007788 WO2003007909A2 (fr) 2001-07-17 2002-07-12 Preparations cosmetiques ou medicales a effet rafraichissant durable

Country Status (2)

Country Link
DE (1) DE10134603A1 (fr)
WO (1) WO2003007909A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004048987B3 (de) * 2004-10-04 2005-12-15 Coty Deutschland Gmbh Kühlende kosmetische Zusammensetzung und deren Verwendung
WO2008044154A2 (fr) * 2006-10-10 2008-04-17 Kimberly-Clark Worldwide, Inc. Compositions rafraîchissantes pour la peau
WO2021244983A1 (fr) 2020-06-04 2021-12-09 Unilever Ip Holdings B.V. Composition de soins personnels pour refroidissement comprenant un polyol et un copolymère séquencé de polyoxyhtylène-polyoxypropylène

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4312656A1 (de) * 1993-04-19 1994-10-20 Beiersdorf Ag Kosmetische und medizinische topische Zubereitungen
GB2292885A (en) * 1994-09-08 1996-03-13 Merck & Co Inc Method of treating hyperlipidemia
US5955081A (en) * 1996-03-22 1999-09-21 Moady Marzook Antipsoriatic compositions, method of making, and method of using
US6242396B1 (en) * 1999-06-28 2001-06-05 L'oreal Cosmetic composition for removing make-up from and/or for cleansing the skin, in the form of a water-in-oil emulsion
WO2002076478A1 (fr) * 2001-03-28 2002-10-03 Council Of Scientific And Industrial Research Bioactivite du palmitate de methyle obtenu a partir de la mangrove salvadora persica l

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605670A (en) * 1984-02-01 1986-08-12 Nitto Electric Industrial Co., Ltd. Method for percutaneously administering metoclopramide
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
CA2177038A1 (fr) * 1993-12-13 1995-06-22 Alrick Vincent Warner Composition de lotion conferant un toucher doux et legerement gras a du papier hygienique
FR2720934B1 (fr) * 1994-06-14 1996-07-12 Oreal Emulsion nettoyante huile-dans-eau ayant l'aspect d'un lait.
FR2721210B1 (fr) * 1994-06-17 1996-08-02 Oreal Composition de nettoyage contenant des grains lipidiques.
ATE182068T1 (de) * 1996-01-10 1999-07-15 Oreal Verwendung eines polyholosids in einer reinigungs- oder abschmink-zusammensetzung und zusammensetzung, die ein polyholisid enthält
US6187695B1 (en) * 1998-12-08 2001-02-13 Kimberly-Clark Worldwide, Inc. Cool feeling tissue product and method

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4312656A1 (de) * 1993-04-19 1994-10-20 Beiersdorf Ag Kosmetische und medizinische topische Zubereitungen
GB2292885A (en) * 1994-09-08 1996-03-13 Merck & Co Inc Method of treating hyperlipidemia
US5955081A (en) * 1996-03-22 1999-09-21 Moady Marzook Antipsoriatic compositions, method of making, and method of using
US6242396B1 (en) * 1999-06-28 2001-06-05 L'oreal Cosmetic composition for removing make-up from and/or for cleansing the skin, in the form of a water-in-oil emulsion
WO2002076478A1 (fr) * 2001-03-28 2002-10-03 Council Of Scientific And Industrial Research Bioactivite du palmitate de methyle obtenu a partir de la mangrove salvadora persica l

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004048987B3 (de) * 2004-10-04 2005-12-15 Coty Deutschland Gmbh Kühlende kosmetische Zusammensetzung und deren Verwendung
US8236331B2 (en) 2004-10-04 2012-08-07 Coty Deutschland Gmbh Cosmetic cooling composition
WO2008044154A2 (fr) * 2006-10-10 2008-04-17 Kimberly-Clark Worldwide, Inc. Compositions rafraîchissantes pour la peau
WO2008044154A3 (fr) * 2006-10-10 2008-10-23 Kimberly Clark Co Compositions rafraîchissantes pour la peau
US8039011B2 (en) 2006-10-10 2011-10-18 Kimberly-Clark Worldwide, Inc. Skin cooling compositions
KR101351177B1 (ko) * 2006-10-10 2014-01-14 킴벌리-클라크 월드와이드, 인크. 피부 냉각 조성물
WO2021244983A1 (fr) 2020-06-04 2021-12-09 Unilever Ip Holdings B.V. Composition de soins personnels pour refroidissement comprenant un polyol et un copolymère séquencé de polyoxyhtylène-polyoxypropylène

Also Published As

Publication number Publication date
DE10134603A1 (de) 2003-02-06
WO2003007909A3 (fr) 2003-12-04

Similar Documents

Publication Publication Date Title
DE10223486A1 (de) Kosmetische und/oder dermatologische Zubereitung mit 2,3-Dibenzylbutyrolactonen
DE10357452A1 (de) Kosmetische Zubereitungen mit einem Gehalt an Licochalcon A oder einem Extrakt aus Radix Glycyrrhizae inflatae, enthaltend Licochalcon A, und organischen Verdicker
EP3406243B1 (fr) Combinaisons de substances actives de la licochalcone a ou d'un extrait de radix glycyrrhizae inflatae contenant de la licochalcone a, du phénoxyéthanol et éventuellement de la glycérine
WO2003007908A2 (fr) Preparations cosmetiques ou dermatologiques ayant une action de refroidissement de longue duree
WO2005053680A1 (fr) Association de 2,3-dibenzylbutyrolactone et de licochalcone-a
EP1401389A2 (fr) Utilisation de carnitine et/ou d'une ou de plusieurs acyl-carnitines pour realiser des preparations cosmetiques ou dermatologiques destinees a accroitre la biosynthese de ceramide
WO2002102338A1 (fr) Carnitine et acylcarnitines destinees au traitement et a la prophylaxie de defauts de pigmentation
EP0937454A2 (fr) Compositions cosmétiques ou dermatologiques contenant des polysaccharides pour protéger des irritations les peaux sensibles
DE10218476A1 (de) Zubereitungen mit Lignanen
WO2002069925A2 (fr) UTILISATION DE COMBINAISONS D'AGENTS ACTIFS COMPOSEES D'ACIDE α-LIPONIQUE ET DE SUBSTANCES DERMATOLOGIQUEMENT ACCEPTABLES PRESENTANT UNE ABSORPTION DE LUMIERE DANS LA GAMME DES UV-A ET UV-B, POUR LA FABRICATION DE PREPARATIONS COSMETIQUES ET DERMATOLOGIQUES
DE10034101A1 (de) Kosmetische oder dermatologische Zubereitungen in Form von Emulsionen, enthaltend Iminodibernsteinsäure
EP1449514A1 (fr) Préparations pour le soin de la peau contenant des rétinoides, des ubiquinones, et de la biotine ou de la carnitine
EP1535603B1 (fr) Préparations cosmétique et dermatologique contenant de la créatine et/ou de la créatinine et des concentrations d'électrolytes d'au moins 50 mmol/l.
DE10217255A1 (de) Verwendung von Phytochelatinen zur Stabilisierung kosmetischer und/oder dermatologischer Zubereitungen
EP1392398A2 (fr) Preparation cosmetique et dermatologique destinee a la regulation et a l'elimination de sebum
DE10355714A1 (de) Wirkstoffkombination aus Kreatin und/oder Kreatinin, Phenoxyethanol und gewünschtenfalls Glycerin
WO2003007909A2 (fr) Preparations cosmetiques ou medicales a effet rafraichissant durable
DE10050155A1 (de) Kosemtische und dermatologische Zubereitungen mit einem Gehalt an Desferrioxamin
DE10111048A1 (de) Verwendung von alpha-Liponsäure zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Regeneration beanspruchter Haut, insbesondere der gealterten Haut
DE20121821U1 (de) Hautpflegeprodukte mit einer Kombination aus Biotin, Ubichinonen und Cyclodextrinen
DE10145111A1 (de) Verwendung von Chitosan zur Stabilisierung kosmetischer und/oder dermatologischer Zubereitungen
WO2002069911A2 (fr) Combinaisons de principes actifs, reunissant de l'acide $g(a)-lipoique et des bioquinones
DE10207274A1 (de) Wirkstoffkombinationen aus Tetrahydrocurcuminoiden und alpha-Liponsäure
DE10146802A1 (de) Vitaminhaltige Hautpflegeprodukte
DE10121090A1 (de) Wirkstoffkombinationen aus Tetrahydrocurcuminoiden und Sericosid und/oder Pflanzenextrakten

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP